Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: Clinical implications of progesterone receptor loss

Virchows Archiv

Volumn 459, Issue 1, 2011, Pages 1-10

  Bogina, Giuseppe ^a   Bortesi, Laura ^a   Marconi, Marcella ^a   Venturini, Marco ^a   Lunardi, Gianluigi ^a   Coati, Francesca ^a   Massocco, Alberto ^a   Manfrin, Erminia ^b   Pegoraro, Cristina ^c   Zamboni, Giuseppe ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Montecchio ^*  (Italy)

Author keywords

Breast carcinoma; HER 2; Hormone receptor; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; DISTANT METASTASIS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SILVER STAINING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79959936894     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1097-7     Document Type: Article

References (49)

1. D Gancberg A Di Leo F Cardoso G Rouas M Pedrocchi M Paesmans A Verhest C Bernard-Marty MJ Piccart D Larsimont 2002 Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 7 1036 1043 12176781 10.1093/annonc/mdf252 1:STN:280:DC%2BD38vitFWgtQ%3D%3D
2. Y Gong DJ Booser N Sneige 2005 Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 103 9 1763 1769 15786420 10.1002/cncr.20987 1:CAS:528: DC%2BD2MXktFGnsbw%3D (Pubitemid 40563246)
3. V Guarneri S Giovannelli G Ficarra S Bettelli A Maiorana F Piacentini E Barbieri MV Dieci R D'Amico G Jovic P Conte 2008 Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 8 838 844 18650259 10.1634/theoncologist.2008-0048 1:CAS:528:DC%2BD1cXhtF2qs7vP
4. PK Idirisinghe AA Thike PY Cheok GM Tse PC Lui S Fook-Chong NS Wong PH Tan 2010 Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance Am J Clin Pathol 133 3 416 429 20154280 10.1309/AJCPJ57FLLJRXKPV
5. C Simmons N Miller W Geddie D Gianfelice M Oldfield G Dranitsaris MJ Clemons 2009 Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 9 1499 1504 19299408 10.1093/annonc/mdp028 1:STN:280:DC%2BD1MrnsVaqtg%3D%3D
6. M Tanner P Jarvinen J Isola 2001 Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer Cancer Res 61 14 5345 5348 11454672 1:CAS:528:DC%2BD3MXlsVChsrw%3D (Pubitemid 32694907)
7. J Zidan I Dashkovsky C Stayerman W Basher C Cozacov A Hadary 2005 Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease Br J Cancer 93 5 552 556 16106267 10.1038/sj.bjc.6602738 1:CAS:528: DC%2BD2MXpsFalur0%3D (Pubitemid 43079998)
8. SR Johnston G Saccani-Jotti IE Smith J Salter J Newby M Coppen SR Ebbs M Dowsett 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 15 3331 3338 7614468 1:CAS:528:DyaK2MXnt1ansb4%3D
9. R Amir M Clemons OC Freedman N Miller RE Coleman C Purdie L Jordan P Quinlan AM Thompson 2010 Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies J Clin Oncol 28 15s
10. J Andersen HS Poulsen 1988 Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer Acta Oncol 27 6A 761 765 3219226 10.3109/02841868809091782 1:STN:280:DyaL1M7hsl2qtg%3D%3D (Pubitemid 19051904)
11. RJ Broom PA Tang C Simmons L Bordeleau AM Mulligan FP O'Malley N Miller IL Andrulis DM Brenner MJ Clemons 2009 Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 5 1557 1562 19443366
12. J Carlsson H Nordgren J Sjostrom K Wester K Villman NO Bengtsson B Ostenstad H Lundqvist C Blomqvist 2004 HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 12 2344 2348 15150568 1:CAS:528:DC%2BD2cXks1aht7k%3D (Pubitemid 38961898)
13. SM Edgerton D Moore 2nd D Merkel AD Thor 2003 erbB-2 (HER-2) and breast cancer progression Appl Immunohistochem Mol Morphol 11 3 214 221 12966347 1:CAS:528:DC%2BD3sXntFSnsbY%3D (Pubitemid 37082057)
14. C Gomez-Fernandez Y Daneshbod M Nassiri C Milikowski C Alvarez M Nadji 2008 Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer Am J Clin Pathol 130 6 879 882 19019763 10.1309/AJCPD1AO3YSYQYNW
15. C Iguchi Y Nio M Itakura 2003 Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome J Surg Oncol 83 2 85 93 12772201 10.1002/jso.10243 1:CAS:528: DC%2BD3sXltFCrs7Y%3D (Pubitemid 36667416)
16. T Kuukasjarvi J Kononen H Helin K Holli J Isola 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 9 2584 2589 8823339 1:CAS:528: DyaK28XlvVGisL0%3D (Pubitemid 26300127)
17. BD Li A Byskosh A Molteni RB Duda 1994 Estrogen and progesterone receptor concordance between primary and recurrent breast cancer J Surg Oncol 57 2 71 77 7934066 10.1002/jso.2930570202 1:CAS:528:DyaK2cXmslOktLw%3D (Pubitemid 24299653)
18. C Liedtke K Broglio S Moulder L Hsu SW Kau WF Symmans C Albarracin F Meric-Bernstam W Woodward RL Theriault L Kiesel GN Hortobagyi L Pusztai AM Gonzalez-Angulo 2009 Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 12 1953 1958 19596702 10.1093/annonc/mdp263 1:STN:280:DC%2BD1MjntFOrtQ%3D%3D
19. MA Locatelli G Curigliano L Fumagalli V Bagnardi G Aurilio P Della Vigna L Monfardini S Giudici G Viale A Goldhirsch 2010 Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 28 18s
20. EE Lower EL Glass DA Bradley R Blau S Heffelfinger 2005 Impact of metastatic estrogen receptor and progesterone receptor status on survival Breast Cancer Res Treat 90 1 65 70 15770528 10.1007/s10549-004-2756-z 1:CAS:528:DC%2BD2MXit1Olu7k%3D (Pubitemid 40487003)
21. P Regitnig W Schippinger M Lindbauer H Samonigg SF Lax 2004 Change of HER-2/neu status in a subset of distant metastases from breast carcinomas J Pathol 203 4 918 926 15258994 10.1002/path.1592 1:CAS:528:DC%2BD2cXmvVajsLk%3D (Pubitemid 39089280)
22. A Santinelli E Pisa D Stramazzotti G Fabris 2008 HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy Int J Cancer 122 5 999 1004 17973263 10.1002/ijc.23051 1:CAS:528: DC%2BD1cXhslGhtb0%3D (Pubitemid 351213996)
23. E Sari G Guler M Hayran I Gullu K Altundag Y Ozisik 2010 Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer Med Oncol 28 1 57 63 20099049 10.1007/s12032-010-9418-2
24. C Shimizu T Fukutomi H Tsuda S Akashi-Tanaka T Watanabe T Nanasawa K Sugihara 2000 c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues J Surg Oncol 73 1 17 20 10649273 10.1002/(SICI)1096-9098(200001)73:1<17::AID-JSO5>3.0.CO;2-2 1:CAS:528:DC%2BD3cXhtFaru7c%3D (Pubitemid 30067528)
25. R Simon A Nocito T Hubscher C Bucher J Torhorst P Schraml L Bubendorf MM Mihatsch H Moch K Wilber A Schotzau J Kononen G Sauter 2001 Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 15 1141 1146 11481385 10.1093/jnci/93.15.1141 1:CAS:528:DC%2BD3MXmtVGqsLc%3D (Pubitemid 32780965)
26. C Tapia S Savic U Wagner R Schonegg H Novotny B Grilli M Herzog AD Barascud I Zlobec G Cathomas L Terracciano G Feichter L Bubendorf 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 3 R31 17511881 10.1186/bcr1676 (Pubitemid 350215176)
27. AM Thompson LB Jordan P Quinlan E Anderson A Skene JA Dewar CA Purdie 2010 Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence in Tissues Study (BRITS) Breast Cancer Res 12 6 R92 21059212 10.1186/bcr2771
28. T van Agthoven M Timmermans LC Dorssers SC Henzen-Logmans 1995 Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer Int J Cancer 63 6 790 793 8847135 10.1002/ijc. 2910630607
29. A Vincent-Salomon M Jouve P Genin P Freneaux B Sigal-Zafrani M Caly P Beuzeboc P Pouillart X Sastre-Garau 2002 HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 8 2169 2173 12001113 10.1002/cncr.10456 1:CAS:528:DC%2BD38Xjs12gtLw%3D (Pubitemid 34411973)
30. WQ Zheng J Lu JM Zheng FX Hu CR Ni 2001 Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression Steroids 66 12 905 910 11711119 10.1016/S0039-128X(01)00121-0 1:CAS:528: DC%2BD3MXot1Omur0%3D (Pubitemid 33064433)
31. WP Carney K Leitzel S Ali R Neumann A Lipton 2007 HER-2/neu diagnostics in breast cancer Breast Cancer Res 9 3 207 17561991 10.1186/bcr1664
32. ME Hammond DF Hayes M Dowsett DC Allred KL Hagerty S Badve PL Fitzgibbons G Francis NS Goldstein M Hayes DG Hicks S Lester R Love PB Mangu L McShane K Miller CK Osborne S Paik J Perlmutter A Rhodes H Sasano JN Schwartz FC Sweep S Taube EE Torlakovic P Valenstein G Viale D Visscher T Wheeler RB Williams JL Wittliff AC Wolff 2010 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 16 2784 2795 20404251 10.1200/JCO.2009.25.6529
33. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
34. G Arpino H Weiss AV Lee R Schiff S De Placido CK Osborne RM Elledge 2005 Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 17 1254 1261 16145046 10.1093/jnci/dji249 1:CAS:528:DC%2BD2MXpvFKjsrk%3D (Pubitemid 41535366)
35. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
36. KI Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell MN Levine 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 20 2103 2111 16707747 10.1056/NEJMoa054504 1:CAS:528: DC%2BD28XkslCku7s%3D (Pubitemid 43736610)
37. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
38. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
39. HJ Kim X Cui SG Hilsenbeck AV Lee 2006 Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer Clin Cancer Res 12 3 Pt 2 1013s 1018s 16467118 10.1158/1078-0432.CCR-05-2128 1:CAS:528:DC%2BD28XhtFeitL8%3D (Pubitemid 43259837)
40. C Arslan E Sari S Aksoy K Altundag 2011 Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature Expert Opin Ther Targets 15 1 21 30 21105765 10.1517/14656566.2011. 537260 1:CAS:528:DC%2BC3cXhsFGlurbJ
41. JM Wu MJ Fackler MK Halushka DW Molavi ME Taylor WW Teo C Griffin J Fetting NE Davidson AM De Marzo JL Hicks D Chitale M Ladanyi S Sukumar P Argani 2008 Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 7 1938 1946 18381931 10.1158/1078-0432.CCR-07- 4082 1:CAS:528:DC%2BD1cXkt1aktbg%3D (Pubitemid 351551102)
42. BL Schlechter Q Yang PS Larson A Golubeva RA Blanchard A de las Morenas CL Rosenberg 2004 Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence J Clin Oncol 22 10 1830 1838 15143075 10.1200/JCO.2004.05.123 1:CAS:528:DC%2BD2cXptlCksr8%3D (Pubitemid 41095173)
43. M Brown K Bauer M Pare 2010 Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004 Breast Cancer Res Treat 120 1 217 227 19629680 10.1007/s10549-009-0469-z
44. SY Park KS Kim TG Lee SS Park SM Kim W Han DY Noh SW Kim 2009 The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer Am J Surg 197 2 266 269 18614146 10.1016/j.amjsurg.2007.11.024 1:CAS:528:DC%2BD1MXhtlSltrg%3D
45. K Tamaki H Sasano T Ishida M Miyashita M Takeda M Amari N Tamaki N Ohuchi 2010 Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients Cancer Sci 101 4 1051 1058 20704578 10.1111/j.1349-7006.2009.01483.x 1:CAS:528:DC%2BC3cXkvFKitrg%3D
46. M Arnedos A Nerurkar P Osin R A'Hern IE Smith M Dowsett 2009 Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann Oncol 20 12 1948 1952 19570962 10.1093/annonc/mdp234 1:STN:280:DC%2BD1MjntFOjsQ%3D%3D
47. DX Nguyen PD Bos J Massague 2009 Metastasis: from dissemination to organ-specific colonization Nat Rev Cancer 9 4 274 284 19308067 10.1038/nrc2622 1:CAS:528:DC%2BD1MXjsFSrsr4%3D
48. X Cui R Schiff G Arpino CK Osborne AV Lee 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 30 7721 7735 16234531 10.1200/JCO.2005.09.004 1:CAS:528: DC%2BD2MXht1WrsrrM (Pubitemid 46291836)
49. M Brankovic-Magic R Jankovic Z Neskovic-Konstantinovic D Nikolic-Vukosavljevic 2002 Progesterone receptor status of breast cancer metastases J Cancer Res Clin Oncol 128 1 55 60 11862473 10.1007/s00432-001-0299- 9 1:CAS:528:DC%2BD38XjsFGnug%3D%3D (Pubitemid 34151123)